Systematic Review: Does Semaglutide Increase Risk of Sudden Vision Loss (NAION)?
A systematic review and meta-analysis critically assesses the emerging evidence linking semaglutide specifically to NAION risk, attempting to clarify a growing safety concern.
Quick Facts
What This Study Found
The systematic review and meta-analysis critically assessed the semaglutide-NAION association, synthesizing all available evidence to quantify the risk.
Key Numbers
How They Did This
Systematic review and meta-analysis with comprehensive literature search for studies examining semaglutide and NAION.
Why This Research Matters
Semaglutide is one of the most prescribed drugs worldwide. Clear evidence about NAION risk is essential for informed prescribing and patient counseling.
The Bigger Picture
This represents the scientific community's response to safety signals — systematically evaluating concerning reports to provide evidence-based guidance rather than relying on case reports and media coverage.
What This Study Doesn't Tell Us
Limited by the quality and quantity of available primary studies; NAION is very rare making statistical detection difficult; publication bias possible.
Questions This Raises
- ?Is the NAION risk specific to semaglutide or shared across all GLP-1 drugs?
- ?Could the association be driven by rapid metabolic changes rather than a direct drug effect?
Trust & Context
- Key Stat:
- Semaglutide-NAION link analyzed First systematic review and meta-analysis specifically addressing this safety concern
- Evidence Grade:
- Systematic review and meta-analysis — highest evidence synthesis methodology, though limited by available primary data.
- Study Age:
- Published in 2026, providing timely evidence during peak semaglutide prescribing and safety investigation.
- Original Title:
- Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.
- Published In:
- Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 15(1), 100245 (2026)
- Authors:
- Chen, Kai-Yang, Chan, Hoi-Chun, Chan, Chi-Ming
- Database ID:
- RPEP-14986
Evidence Hierarchy
Frequently Asked Questions
Can semaglutide cause blindness?
NAION causes sudden vision loss in one eye and is very rare. This systematic review examines whether semaglutide slightly increases this already-low risk. Even if an association exists, the absolute risk would be very small.
Should I stop taking semaglutide because of NAION concerns?
Don't stop medication without consulting your doctor. This review aims to clarify whether the risk is real and how large it might be. For most patients, the metabolic benefits of semaglutide likely outweigh any small vision risk.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14986APA
Chen, Kai-Yang; Chan, Hoi-Chun; Chan, Chi-Ming. (2026). Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 15(1), 100245. https://doi.org/10.1016/j.apjo.2025.100245
MLA
Chen, Kai-Yang, et al. "Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.." Asia-Pacific journal of ophthalmology (Philadelphia, 2026. https://doi.org/10.1016/j.apjo.2025.100245
RethinkPeptides
RethinkPeptides Research Database. "Does semaglutide increase the risk of non-arteritic anterior..." RPEP-14986. Retrieved from https://rethinkpeptides.com/research/chen-2026-does-semaglutide-increase-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.